These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 18425953

  • 21. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA, Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams.
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [Abstract] [Full Text] [Related]

  • 22. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
    Löfvenberg E, Wahlin A.
    Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
    [Abstract] [Full Text] [Related]

  • 23. Antiplatelet therapy and anticoagulation in patients with hypertension.
    Griffin G.
    Am Fam Physician; 2005 Mar 01; 71(5):897-9. PubMed ID: 15768617
    [Abstract] [Full Text] [Related]

  • 24. Antiplatelet and anticoagulation for patients with prosthetic heart valves.
    Little SH, Massel DR.
    Cochrane Database Syst Rev; 2003 Mar 01; (4):CD003464. PubMed ID: 14583979
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 01; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun 01; 15(83):83-6. PubMed ID: 16764090
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
    Shaikh MS, Shaikh MU, Adil SN, Khurshid M, Ahmed ZA.
    J Ayub Med Coll Abbottabad; 2016 Jun 01; 28(2):293-297. PubMed ID: 28718562
    [Abstract] [Full Text] [Related]

  • 32. Anticoagulants versus antiplatelet agents for acute ischaemic stroke.
    Berge E, Sandercock P.
    Cochrane Database Syst Rev; 2002 Jun 01; (4):CD003242. PubMed ID: 12519590
    [Abstract] [Full Text] [Related]

  • 33. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Evidence Review Committee Members, Bittl JA, Baber U, Bradley SM, Wijeysundera DN.
    Circulation; 2016 Sep 06; 134(10):e156-78. PubMed ID: 27026019
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-A matched nationwide population-based study.
    Enblom-Larsson A, Renlund H, Andréasson B, Holmberg H, Liljeholm M, Själander A.
    Br J Haematol; 2024 May 06; 204(5):1740-1751. PubMed ID: 38351734
    [Abstract] [Full Text] [Related]

  • 37. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É, Marton I, Kiss-László Z, Kotosz B, Széll M, Borbényi Z.
    Eur Rev Med Pharmacol Sci; 2014 May 06; 18(24):3810-8. PubMed ID: 25555871
    [Abstract] [Full Text] [Related]

  • 38. Anagrelide: a review of its use in the management of essential thrombocythaemia.
    Wagstaff AJ, Keating GM.
    Drugs; 2006 May 06; 66(1):111-31. PubMed ID: 16398570
    [Abstract] [Full Text] [Related]

  • 39. Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism.
    Watson HG, Chee YL.
    Blood Rev; 2008 Mar 06; 22(2):107-16. PubMed ID: 18226435
    [Abstract] [Full Text] [Related]

  • 40. Antiplatelet therapy in the management of myeloproliferative neoplasms.
    Alvarez-Larrán A, Besses C.
    Curr Hematol Malig Rep; 2014 Dec 06; 9(4):319-23. PubMed ID: 25120015
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.